Fannie/Freddie Politics Board (Poltics Allowed~Non-Moderated) : Ya, I read something similar that was po...

Ya, I read something similar that was posted.

nagoya1 · 2024-07-13T14:53:51.8170000Z

Ya, I read something similar that was posted. With the amount of time that it takes lawsuits to get to court, we can actually see it with the GSEs how deadbeat Blamebutt is extending and taking his sweet azz time, with him feeling no pressure whatsover coming from the judiciary, one has to wonder how long cases can be dragged and extended either by incompetence or by malicious intent. It's so bad that these govrats are above the law, I'd hate to be at the starting block once again with this CON conservatorship malarkey. The finish line seems to be only one curve ahead, but the crooks keep on finding ways to screw GSE shareholders just a little longer. It seems that I'm not the only one that has lost emoji access on FNMA, I can't share brown emojis with the well deserving miscreants. Hoping that Trump says something about the GSEs this week, it would be great for us....

Play Episode

10min

Proactive - Interviews for investors

Vinyl Group CEO on expansion, profitability & strategy after H1 revenue soars 770%

Vinyl Group Ltd CEO Josh Simons talked with Proactive's Jonathan Jackson about the company's strong financial growth, recent acquisitions, and future expansion plans. The company recently reported a 770.2% revenue increase in its latest half-year results. Simons highlighted the annual revenue run rate growth from $2 million to $20 million, emphasising that Vinyl Group is executing its aggressive acquisition strategy while optimising operations for profitability. A key topic of discussion was the acquisition of Concrete Playground, a move that expands Vinyl Group’s media and advertising reach. Simons explained that integrating Concrete Playground into the company’s existing infrastructure creates significant cross-selling opportunities whilst also strengthening Vinyl Group's market position. Looking ahead, Simons discussed the global expansion potential of Vinyl Group’s tech platforms. He noted that for the first time, the company’s tech segment outperformed its media business in revenue, signaling a shift toward scalable, international growth. “The pathway we’re on is clear—we’re optimising, moving towards profitability, and laying the groundwork for further expansion,” Simons said. For more interviews and updates, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for future updates. #VinylGroup #Music #MusicIndustry #JoshSimons #BusinessGrowth #TechExpansion #InvestorNews #MusicTech #ProactiveInvestors

Proactive - Interviews for investors

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Proactive - Interviews for investors

NSX CEO highlights mining focus & direct listings as key growth drivers for 2025

National Stock Exchange of Australia CEO Max Cunningham talked with Proactive's Angela Harmantas from the PDAC conference in Toronto about the exchange’s role in the Australian market, its focus on mining companies, and its expansion plans. Cunningham explained that the NSX is one of two active stock exchanges in Australia with a tier-one license, allowing it to serve all investors, including retail. He highlighted that around one-third of the exchange’s listings are mining-related, with strong growth potential in the sector. Cunningham noted that NSX is working to fill a gap in the Australian venture market and is focusing on attracting mining companies, especially from regions like Perth. He also emphasized the importance of international relationships, mentioning cross-listing agreements with Canadian exchanges such as the CSE and TSX, as well as OTC Markets. Looking ahead to 2025, Cunningham discussed the challenges of IPOs due to regulatory hurdles and capital-raising difficulties. Instead, the NSX is prioritizing direct listings, which allow companies to go public without raising capital upfront. He stated that NSX is seeing increased interest from firms moving from the incumbent Australian exchange, as well as from Canadian companies seeking dual listings. #NSX #StockMarket #MiningStocks #IPOs #DirectListings #PDAC2025 #Investing #AustralianMarkets #DualListings #CapitalMarkets

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Followers	61
Posts	10593
Boards Moderated	0
Alias Born	11/12/2010

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free